Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

@article{Lam2009EfficacyO1,
  title={Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.},
  author={Dennis S. C. Lam and Timothy Y Y Lai and Vincent Wing-hong Lee and Carmen Kar-mun Chan and David T. L. Liu and Shaheeda Mohamed and C. L. Li},
  journal={Retina},
  year={2009},
  volume={29 3},
  pages={292-9}
}
PURPOSE To evaluate the efficacy of intravitreal injections of two different dosages of bevacizumab (Avastin) for treating diffuse diabetic macular edema. METHODS Fifty-two eyes of 52 patients with diabetic macular edema were randomized to receive three monthly intravitreal injections of 1.25 mg or 2.5 mg bevacizumab. Patients were observed for 6 months and optical coherence tomography central foveal thickness, logMAR best-corrected visual acuity (BCVA), and adverse events were assessed… CONTINUE READING

From This Paper

Topics from this paper.
37 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…